NCT01453725View on ClinicalTrials.gov

Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)

PHASE3CompletedINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

February 13, 2012

Primary Completion Date

March 11, 2014

Study Completion Date

January 15, 2015

Conditions

Spondylitis, Ankylosing

Interventions

BIOLOGICAL

Golimumab

Golimumab 50 mg SC injection every 4 weeks

BIOLOGICAL

Placebo

Placebo SC injection every 4 weeks

Sponsors

Collaborators (1)

Johnson & Johnson

All Listed Sponsors

collaborator

Johnson & Johnson

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY